BLRX Relative Valuation
BLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BLRX is overvalued; if below, it's undervalued.
Historical Valuation
BioLine RX Ltd (BLRX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 5.61 is considered Overvalued compared with the five-year average of -1.56. The fair price of BioLine RX Ltd (BLRX) is between 1.06 to 2.50 according to relative valuation methord. Compared to the current price of 3.22 USD , BioLine RX Ltd is Overvalued By 28.68%.
Relative Value
Fair Zone
1.06-2.50
Current Price：3.22
28.68%
Overvalued
-1.57
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
BioLine RX Ltd. (BLRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.20. The thresholds are as follows: Strongly Undervalued below -3.75, Undervalued between -3.75 and -2.47, Fairly Valued between 0.08 and -2.47, Overvalued between 0.08 and 1.36, and Strongly Overvalued above 1.36. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.04
EV/EBIT
BioLine RX Ltd. (BLRX) has a current EV/EBIT of -0.04. The 5-year average EV/EBIT is -1.67. The thresholds are as follows: Strongly Undervalued below -4.53, Undervalued between -4.53 and -3.10, Fairly Valued between -0.23 and -3.10, Overvalued between -0.23 and 1.20, and Strongly Overvalued above 1.20. The current Forward EV/EBIT of -0.04 falls within the Overvalued range.
5.93
PS
BioLine RX Ltd. (BLRX) has a current PS of 5.93. The 5-year average PS is 12.99. The thresholds are as follows: Strongly Undervalued below -73.14, Undervalued between -73.14 and -30.08, Fairly Valued between 56.05 and -30.08, Overvalued between 56.05 and 99.12, and Strongly Overvalued above 99.12. The current Forward PS of 5.93 falls within the Historic Trend Line -Fairly Valued range.
-1.40
P/OCF
BioLine RX Ltd. (BLRX) has a current P/OCF of -1.40. The 5-year average P/OCF is -0.62. The thresholds are as follows: Strongly Undervalued below -2.69, Undervalued between -2.69 and -1.66, Fairly Valued between 0.41 and -1.66, Overvalued between 0.41 and 1.44, and Strongly Overvalued above 1.44. The current Forward P/OCF of -1.40 falls within the Historic Trend Line -Fairly Valued range.
-4.98
P/FCF
BioLine RX Ltd. (BLRX) has a current P/FCF of -4.98. The 5-year average P/FCF is -0.03. The thresholds are as follows: Strongly Undervalued below -2.86, Undervalued between -2.86 and -1.45, Fairly Valued between 1.39 and -1.45, Overvalued between 1.39 and 2.81, and Strongly Overvalued above 2.81. The current Forward P/FCF of -4.98 falls within the Strongly Undervalued range.
BioLine RX Ltd (BLRX) has a current Price-to-Book (P/B) ratio of 430.42. Compared to its 3-year average P/B ratio of 122.30 , the current P/B ratio is approximately 251.93% higher. Relative to its 5-year average P/B ratio of 75.47, the current P/B ratio is about 470.31% higher. BioLine RX Ltd (BLRX) has a Forward Free Cash Flow (FCF) yield of approximately -98.16%. Compared to its 3-year average FCF yield of -96.75%, the current FCF yield is approximately 1.46% lower. Relative to its 5-year average FCF yield of -69.99% , the current FCF yield is about 40.24% lower.
435.37
P/B
Median3y
122.30
Median5y
75.47
-92.92
FCF Yield
Median3y
-96.75
Median5y
-69.99
Competitors Valuation Multiple
The average P/S ratio for BLRX's competitors is 1.98, providing a benchmark for relative valuation. BioLine RX Ltd Corp (BLRX) exhibits a P/S ratio of 5.93, which is 200.00% above the industry average. Given its robust revenue growth of -91.36%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BLRX decreased by 61.95% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -117.78 to -228.81.
The secondary factor is the P/E Change, contributed -64.86%to the performance.
Overall, the performance of BLRX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is BioLine RX Ltd (BLRX) currently overvalued or undervalued?
What is BioLine RX Ltd (BLRX) fair value?
How does BLRX's valuation metrics compare to the industry average?
What is the current P/B ratio for BioLine RX Ltd (BLRX) as of Dec 05 2025?
What is the current FCF Yield for BioLine RX Ltd (BLRX) as of Dec 05 2025?
What is the current Forward P/E ratio for BioLine RX Ltd (BLRX) as of Dec 05 2025?